![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2022/11/03/2547576/0/en/Aramis-Biosciences-Completes-Enrollment-of-its-Phase-II-Clinical-Trial-Evaluating-A197-for-the-Treatment-of-Dry-Eye-Disease.html
https://www.globenewswire.com/news-release/2022/02/28/2393089/0/en/Aramis-Biosciences-Announces-First-Patient-Dosed-in-Phase-II-Clinical-Trial-Evaluating-A197-for-the-Treatment-of-Dry-Eye-Disease.html
https://www.globenewswire.com/news-release/2022/01/11/2364781/0/en/Aramis-Biosciences-Announces-FDA-Clearance-of-IND-Application-for-A197-a-Novel-Immunomodulatory-Agent-for-the-Treatment-of-Dry-Eye-Disease.html